KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Raw Materials: 2010-2021

Historic Raw Materials for Biomarin Pharmaceutical (BMRN) over the last 11 years, with Sep 2021 value amounting to $75.3 million.

  • Biomarin Pharmaceutical's Raw Materials rose 1.99% to $75.3 million in Q3 2021 from the same period last year, while for Sep 2021 it was $75.3 million, marking a year-over-year increase of 1.99%. This contributed to the annual value of $76.7 million for FY2020, which is 3.00% up from last year.
  • As of Q3 2021, Biomarin Pharmaceutical's Raw Materials stood at $75.3 million, which was down 10.02% from $83.7 million recorded in Q2 2021.
  • Biomarin Pharmaceutical's Raw Materials' 5-year high stood at $83.7 million during Q2 2021, with a 5-year trough of $46.5 million in Q2 2018.
  • Over the past 3 years, Biomarin Pharmaceutical's median Raw Materials value was $75.3 million (recorded in 2021), while the average stood at $74.7 million.
  • Per our database at Business Quant, Biomarin Pharmaceutical's Raw Materials skyrocketed by 49.60% in 2018 and then fell by 4.42% in 2021.
  • Biomarin Pharmaceutical's Raw Materials (Quarterly) stood at $49.9 million in 2017, then skyrocketed by 49.60% to $74.6 million in 2018, then dropped by 0.23% to $74.4 million in 2019, then increased by 3.00% to $76.7 million in 2020, then increased by 1.99% to $75.3 million in 2021.
  • Its Raw Materials stands at $75.3 million for Q3 2021, versus $83.7 million for Q2 2021 and $78.6 million for Q1 2021.